ORIGINAL RESEARCH article
Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1542888
This article is part of the Research TopicScreening and discovering novel biological biomarkers by omic-data to revolutionize tumor managementView all 8 articles
Expression and Clinical Significance of FANCI Gene in Pan-Cancer: A Comprehensive Analysis Based on Multi-Omics Data
Provisionally accepted
- 1First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China
- 2Key Laboratory of Hepatosplenic Surgery, Ministry of Education, First Affiliated Hospital of Harbin Medical University, Harbin, Jilin Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The FANCI gene, an essential element of the Fanconi anemia pathway, has been associated with a variety of cancer types. This investigation seeks to clarify the expression profiles, prognostic relevance, and diagnostic capabilities of FANCI across multiple malignancies, along with its links to immune cell infiltration, genetic alterations, protein-protein interactions, and functional roles. By utilizing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, we conducted a comprehensive analysis of FANCI mRNA expression using R software and visualized the results with the ggplot2 package. Prognostic and diagnostic evaluations were conducted using Xiantao tools to produce survival and receiver operating characteristic (ROC) curves. The examination of genetic variation was facilitated through cBioPortal, while DNA methylation and mRNA modifications were analyzed utilizing UALCAN and SangerBox 3.0. Correlations with immune responses were assessed via the EPIC platform and SangerBox 3.0. Additionally, we constructed protein-protein interaction networks employing the STRING database and Cytoscape software. Functional enrichment analyses encompassed Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA). The CancerSEA database was also utilized for single-cell level investigation of FANCI's association with the functional states of cancer. Our findings reveal that FANCI is significantly upregulated in the majority of tumor types when compared to normal tissues, with increased protein levels observed in several cancers, including colorectal adenocarcinoma (COAD) and pancreatic adenocarcinoma (PAAD). Elevated FANCI expression is associated with unfavorable prognoses in cancers such as adrenocortical carcinoma (ACC) and liver hepatocellular carcinoma (LIHC). Methylation assessments demonstrated a robust inverse correlation between FANCI promoter methylation and its expression in LIHC. Moreover, FANCI expression was found to be connected to immune cell infiltration and tumor mutation burden in select cancers. In summary, FANCI presents as a promising biomarker for cancer prognosis and diagnosis, with potential implications for therapeutic interventions. Subsequent investigations should concentrate on elucidating the mechanistic functions of FANCI in cancer development and assessing its viability as a therapeutic target.
Keywords: FANCI, Pan-cancer, DNA damage repair, Gene Expression, Clinical significance, biomarker
Received: 10 Dec 2024; Accepted: 07 Apr 2025.
Copyright: © 2025 Zhao, Li, Li, Cui and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yifeng Cui, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China
Zhaoyang Lu, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.